Atrial fibrillation (AF) is a heart condition, characterised by an irregular heartbeat. Not only does AF present with multiple symptoms, it is also associated with an increased risk of stroke, imposing burden on a patient’s quality of life and functional health. This prompts the need for therapeutic agents that lower the risk of stroke, without increasing the risk of bleeding. This module mainly presents data on edoxaban from the large ENGAGE AF-TIMI 48 clinical trial featuring patients with AF. Upon completion of this module, participants should be able to identify patients with AF that may benefit from edoxaban therapy for optimal outcomes.
Professor Alan Fong
Sarawak Heart Centre
Who should participate:
Please read thoroughly & understand the module before attempting the assessment questions.
Terms & Conditions:
Participants must obtain a minimum score of 7/10 (70%) to be awarded 1 point.
MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points.
The modules/articles are best viewed with: Google Chrome, Firefox, Internet Explorer, Safari or any other W3C standards-compliant browser may be required to view the modules.